Stock Alert for Complete Genomics Inc. (GNOM)
  • Stock Alert for Ku6 Media Co. Ltd. (KUTV)
  • Stock Alert for Seven Arts Entertainment Inc. (SAPX)
  • " />

    Stock Alert for Complete Genomics Inc. (GNOM)

    Complete Genomics Inc. (GNOM) is a life sciences company that has developed and commercialized an innovative DNA sequencing platform that it believes will become the preferred solution for complete human genome sequencing and analysis. The Complete Genomics Analysis Platform, or CGA™ Platform, combines the Company’s proprietary human genome sequencing technology with its advanced informatics and data management software.  GNOM offers this solution as an innovative, end-to-end, outsourced service and provide customers with data that is immediately ready to be used for genome-based research. Its CGA™ Service solution provides academic and biopharmaceutical researchers with complete human genomic data and analysis at an unprecedented quality, cost and scale. GNOM generated revenue of $9.4 million for fiscal 2010, which compares to revenue of $0.6 million in fiscal 2009.

    Share Statistics (13-Feb-11)   FY












    Symbol GNOM Revenue, $Mn 0.62 9.39 1414.5% 4.16 4.18 0.5%
    Current price $4.66 Gross marg. -711.3% -111.9% -84.3% -44.5% -95.7% 115.1%
    52wk Range: $2.21-$18.55 Oper. margin -507.5% -498.4%
    Avg Vol (3m): 676,203 Net margin -5798.4% -614.4% -89.4% -491.8% -517.0% 5.1%
    Market Cap. 154.63M              
    Shares Outstanding 33.18M EPS, $ -386.56 -13.60 -96.5% -21.87 -0.65 -97.0%

    Source:, SEC Filings.

    Investment Highlights

    Shares of GNOM have gained 33.1% in the last five days and 62.9% in the last month.  Year-to-date, the stock is down 41.4%.

    Shares of GNOM spiked as much as 65% to reach an intraday high of $5.42 Monday, boosted by news the Company has entered into a deal with the Mayo Clinic’s Center for Individualized Medicine to provide large-scale genomic sequencing services.

    The Center for Individualized Medicine, which operates a comprehensive sequencing laboratory in its own Medical Genome Facility, determined that collaboration with GNOM could supplement the services available to its community of medical researchers, the release said. The terms of the deal provide for Mayo Clinic to send genetic material to Complete Genomics for sequencing and analysis. It will continue to operate and invest in its Medical Genome Facility.

    The financial details of the agreement were not revealed.

    “It is exciting to see a world-renowned healthcare organization like Mayo Clinic take the next step towards bringing high-quality whole genome sequencing data into the clinic. They clearly recognize its potential to personalize treatment options and improve the future quality of patient care,” commented Leroy Hood M.D., Ph.D., president of the Institute for Systems Biology and a member of GNOM’s scientific advisory board. “This is a big step toward the realization of personalized medicine.”

    According to the release, projects will be coordinated with the Center of Individualized Medicine’s Medical Genome Facility and will help expedite Mayo Clinic’s translational genomics-based programs. Through these initiatives, Mayo Clinic will develop best practices for using genetic information to guide patient care.

    Shares of GNOM added 41.6% to close Monday’s trade at $4.66.  Over the last 52 weeks, the stock has ranged from a low of $2.21 to a high of $18.55.  It is currently above  its 50-day moving average of $2.99 and below its 200-day moving average of $5.51.


    Financial Summary

    GNOM reported revenue of $4.2 million for the third quarter ended September 30, 2011, compared to $4.2 million in the third quarter of 2010. The Company recognized revenue for over 700 genomes compared to over 300 genomes recognized in the comparable quarter of the prior year.

    Costs and operating expenses were $25.0 million compared to $14.9 million in the third quarter of 2010.

    GNOM realized a net loss of $21.6 million compared to $20.5 million in the third quarter of 2010. The net loss for the latest period included an $8.8 million non-cash expense resulting from the accounting adjustment to market value of certain equity securities.

    The Company’s backlog as of September 30, 2011, was about $24 million and 4,800 genomes. It ended the third quarter of 2011 with $105.1 million in cash, cash equivalents and short-term investments.


    Financial Strength (13-Feb-2012)




    S&P 500

    Quick Ratio (MRQ) 4.96 3.19 1.81 0.58
    Current Ratio (MRQ) 5.11 4.05 2.32 0.93
    LT Debt to Equity (MRQ) 17.94 25.40 26.55 170.45
    Total Debt to Equity (MRQ) 22.96 28.40 36.23 227.63
    Interest Coverage (TTM) -4.64 52.09 2.49 27.20

    Source:, SEC Filings.

    Technical Analysis


    GNOM is above the upper Bollinger Band, implying that it is currently extended from its recent trend. Be aware, however, that a cross outside of the Bollinger Bands can sometimes be a signal of trend strength and not, necessarily, trend reversal.

    The MACD for GNOM currently indicates a strong bullish signal for two reasons. First, the MACD is above the signal line, a 9-day moving average. Second, the MACD is above 0, which implies that the underlying moving averages are trending higher.

    Comparative Analysis

    Company Name Ticker Price per Mrkt. Cap. P/E P/S
    Feb13-2011 symbol Share, $ $ Mn 2011 2012 2011 2012
    Illumina Inc. ILMN 54.05 6.57B 36.77 31.79 5.81 5.34
    Life Technologies Corp. LIFE 49.81 8.88B 12.45 11.45 2.32 2.24
    Biotechnology Median       17.61 n/a 8.99 n/a
    Complete Genomics Inc. GNOM 4.66 154.63M n/a n/a 7.72 4.49

    Source: Thomson Financial

    DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

    The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

    Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

    Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

    Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

    We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

    To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

    We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at

    Leave a Reply

    Your email address will not be published. Required fields are marked *